Dr. Jonasch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
- McGill University Faculty of MedicineClass of 1992
Certifications & Licensure
- FL State Medical License 2021 - Present
- WA State Medical License 2023 - 2026
- AZ State Medical License 2023 - 2026
- TN State Medical License 2023 - 2026
- OK State Medical License 2020 - 2025
- GA State Medical License 2023 - 2025
- MS State Medical License 2023 - 2024
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2012-2013
Clinical Trials
- Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma Start of enrollment: 2005 Feb 01
- Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2005 Jun 01
- Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Start of enrollment: 2006 May 01
- Join now to see all
Publications & Presentations
PubMed
- VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.Melissa M Wolf, Matthew Z Madden, Emily N Arner, Jackie E Bader, Xiang Ye, Logan Vlach, Megan L Tigue, Madelyn D Landis, Patrick B Jonker, Zaid Hatem, KayLee K Steiner...> ;The Journal of Clinical Investigation. 2024 Apr 15
- YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial.Chad Tang, Kieko Hara, Alexander D Sherry, Alejandra G Serrano, Larisa V Kostousov, Sharia D Hernandez, Wei Lu, Li Shen, Amishi Y Shah, Eric Jonasch, Jose A Karam, Sur...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
- Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.Lliopoulos, O., Beckermann, K., Oudard, S., Iversen, A., Goldberg, C., Fu, W., Perini, R., Liu, Y., Linehan, W., Else, T., Jonasch, E., Narayan, V., Maughan, B., Maran...> ;Clinical Cancer Research. 2024 Feb 23
- Join now to see all
Journal Articles
- VHL Substrate Transcription Factor ZHX2 as an Oncogenic Driver in Clear Cell Renal Cell CarcinomaEric Jonasch, Xian Chen, William Y Kim, W Kimryn Rathmell, Science Magazine
Lectures
- Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Enrichment and Optimization of Anti-VEGF Targeted Strategies in Metastatic Renal Cell Carcinoma2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Molecular biology and pathogenesis of von Hippel-Lindau diseaseJonasch E, Plon SE
http://www.uptodate.com/contents/molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease
UpToDate, Wolters Kluwer Health - 2012-06-19 - Immunotherapy of renal cell carcinomaJonasch E, George D
http://www.uptodate.com/contents/immunotherapy-of-renal-cell-carcinoma
UpToDate, Wolters Kluwer Health - 2012-09-17 - Clinical features, diagnosis, and management of von Hippel-Lindau diseaseJonasch E, Plon SE
http://www.uptodate.com/contents/clinical-features-diagnosis-and-management-of-von-hippel-lindau-dis
UpToDate, Wolters Kluwer Health - 2013-02-05
Press Mentions
- Clinical Trials for Kidney Cancer: What to KnowDecember 26th, 2022
- 22 Research Highlights from the Past YearDecember 19th, 2022
- Ground-Breaking New Method for Multi-Cancer Early DetectionDecember 7th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: